Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Observation - Complaining about how cheap a stock
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Dec 17, 2020 11:09pm
116 Views
Post# 32137644

RE:RE:Observation - Complaining about how cheap a stock

RE:RE:Observation - Complaining about how cheap a stock
MrMugsy wrote:
schocor wrote: This is a weird little board. Most come on here to complain about how cheap the stock is. "It is about the same price as it was in March - airlines are doing better" - clearly not written by a CFA. "All the stock does is go down" - what about the fundamentals of the company there Einstein? It is pretty clear to me that a lot of people that SHOULD have known better bought this stock with instant $$$ signs in their eyes. Scazenfreud is - I believe - the emotion elicited when I read their responses on here.


Well said Schocor.
I like the way you think.




And the fundamentals is why we're here ... and ... why Knight has ventured into Latin America.  Patience is required as they build it.

"Latin America Pharmaceutical Products CMO Market was valued at US$ 13,266.5 Mn in 2019 and is forecast to reach a value of US$ 40,070.3 Mn by 2027 at a CAGR of 14.8% between 2020 and 2027."
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities